^
Association details:
| Biomarker: | HLA-A*02:01 |
|---|---|
| Cancer: | Cutaneous Melanoma |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) + Kimmtrak (tebentafusp-tebn) (CD3 agonist, gp100 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study
Published date:
06/08/2023
Excerpt:
In this open-label, multicenter, phase 1b, dose-escalation trial, HLA-A*02:01-positive patients with mCM received weekly intravenous tebentafusp with increasing monthly doses of durvalumab and/or tremelimumab...Tebentafusp with durvalumab demonstrated promising efficacy in heavily pretreated patients with mCM, including those who progressed on prior anti-PD(L)1.
Trial ID:
